ReviewInternational journal of molecular sciences2024
Targeting
Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Prognostic significance of KRAS G12C versus non-G12C RAS mutations in metastatic colorectal cancer: a systematic review and meta-analysis.The oncologist · 2026Pooled it
- Efficacy and safety of KRAS -G12C inhibitors in colorectal cancer: a systematic review of clinical trials.Medical oncology (Northwood, London, England) · 2025Pooled it
- KRAS in Colorectal Cancer: Tumorigenesis, Surgical Implications and Evolving Treatment Target.Current oncology (Toronto, Ont.) · 2026Review
- KRAS G12C-mutated Metastatic Colorectal Cancer: Current Therapeutic Strategies and Future Directions.Journal of gastrointestinal cancer · 2026Review
- Enhancing Targeted Colorectal Cancer Therapies with Natural Products: Mechanistic Pathways.Biomedicines · 2026Review
- The Heterogeneity of Mucinous Colorectal Adenocarcinoma-Histologic and Molecular Phenotypes Drive Prognostic Outcomes.Cancers · 2026Article
- [Relationship betweenZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026Article
- KRAS mutation subtypes refine prognostic stratification in colorectal cancer: a retrospective cohort study.Journal of gastrointestinal oncology · 2026Article
- Review
- UnlockingCurrent oncology (Toronto, Ont.) · 2026Review
- Association of RAS mutational status with clinical outcomes in metastatic colorectal cancer treated with trifluridine/tipiracil or regorafenib.Scientific reports · 2026Article
- Gene, genetics and genetic medicines in gastroenterology: Current status and its future.World journal of gastroenterology · 2026Review
- Identification of KRAS mutation in rectal cancer based on a 2.5D deep learning model.Frontiers in oncology · 2026Article
- Liquid biopsy - a narrative review with an update on current US governmental clinical trials targeting immunotherapy.Future science OA · 2025Review
- Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges.Signal transduction and targeted therapy · 2025Review
- A Hybrid In Silico Approach for Identifying Dual VEGFR/RAS Inhibitors as Potential Anticancer and Anti-Angiogenic Agents.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Management of Elderly Colorectal Cancer Patients: A Comprehensive Review Encompassing Geriatric Assessment.Cancers · 2025Review
- CodeBreaK or code blue? Assessing sotorasib's vital signs in metastatic colorectal cancer.Cancer · 2025Article
- KRAS G12C Inhibition in Solid Tumors: Biological Breakthroughs, Clinical Evidence, and Open Challenges.Cancers · 2025Review
- Immune Modulation Through KIR-HLA Interactions Influences Cetuximab Efficacy in Colorectal Cancer.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kirsten rat sarcoma virus oncogene homolog (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.